Weill David 4
4 · TransMedics Group, Inc. · Filed Feb 28, 2023
Insider Transaction Report
Form 4
Weill David
Director
Transactions
- Sale
Common Stock
2023-02-27$77.64/sh−964$74,845→ 14,970 total - Sale
Common Stock
2023-02-27$76.51/sh−4,970$380,255→ 10,000 total - Exercise/Conversion
Common Stock
2023-02-27$14.20/sh+5,934$84,263→ 15,934 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-02-27−5,934→ 10,000 totalExercise: $14.20Exp: 2030-06-04→ Common Stock (5,934 underlying)
Footnotes (4)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $77.63 to $77.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $76.44 to $76.65, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]A Form 4 filed by the reporting person on November 14, 2022 inadvertently overstated the total number of shares held by the reporting person by 3,500 shares. The updated amounts reported here correct that error and reflect the reporting person's holdings.
- [F4]The option is fully vested.